Clinical Trials Logo

Clinical Trial Summary

Celldex endeavors to make investigational products available to patients with life-threatening diseases who have exhausted other treatment options and where there is a reasonable expectation of benefit over risk. Requests for expanded access to rindopepimut in patients with EGFRvlll expressing recurrent glioblastoma will be considered.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03068650
Study type Expanded Access
Source Celldex Therapeutics
Contact
Status No longer available
Phase N/A

See also
  Status Clinical Trial Phase
Terminated NCT04681677 - Recurrent GBM Treated With Neurosurgical Resection and IORT Using the Xoft Axxent eBx System and Bevacizumab Phase 2
Terminated NCT04763031 - Recurrent GBM With Maximal Neurosurgical Removal and Treatment With IORT N/A
Active, not recruiting NCT05370508 - A Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Subjects With Recurrent GBM Phase 1/Phase 2